肿瘤突变负荷对免疫检查点阻断后癌症预后的剂量依赖性效应：因果关系 - Suppr

Suppr

超能文献

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.

作者信息

Zheng Ming

机构信息

Institute of Military Cognition and Brain Sciences, Academy of Military Medical Sciences, Beijing, China.

Beijing Institute of Basic Medical Sciences, Beijing, China.

出版信息

Front Immunol. 2022 Jun 3;13:853300. doi: 10.3389/fimmu.2022.853300. eCollection 2022.

DOI:10.3389/fimmu.2022.853300

PMID:35720282

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9203856/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed01/9203856/3c8b6d3d92ee/fimmu-13-853300-g001.jpg

相似文献

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.肿瘤突变负荷对免疫检查点阻断后癌症预后的剂量依赖性效应：因果关系

Front Immunol. 2022 Jun 3;13:853300. doi: 10.3389/fimmu.2022.853300. eCollection 2022.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.肿瘤突变负担作为免疫治疗生物标志物的发展：在肿瘤学临床中的应用。

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

Leveraging big data of immune checkpoint blockade response identifies novel potential targets.利用免疫检查点阻断反应的大数据确定新的潜在靶点。

Ann Oncol. 2022 Dec;33(12):1304-1317. doi: 10.1016/j.annonc.2022.08.084. Epub 2022 Aug 30.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.免疫治疗在 Epstein-Barr 病毒相关性胃癌中的疗效和预测生物标志物。

J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004080.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。

Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.循环肿瘤 DNA 肿瘤突变负荷（ctDNA TMB）在非小细胞肺癌中的临床意义。

Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.

Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).一种预测免疫检查点阻断反应的新型基因组特征：来自项目基因组证据肿瘤信息交换（GENIE）的泛癌分析。

Cancer Genet. 2021 Nov;258-259:61-68. doi: 10.1016/j.cancergen.2021.08.004. Epub 2021 Aug 28.

Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.联合生物标志物预测接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者临床结局的价值。

Clin Lung Cancer. 2021 Nov;22(6):500-509. doi: 10.1016/j.cllc.2021.03.017. Epub 2021 Mar 27.

Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4 和程序性死亡配体 1 在 Epstein-Barr 病毒相关鼻咽癌中的表达。

Appl Immunohistochem Mol Morphol. 2021 Jul 1;29(6):401-408. doi: 10.1097/PAI.0000000000000903.

引用本文的文献

Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer.微卫星不稳定性（MSI）和肿瘤突变负荷（TMB）作为前列腺癌中免疫检查点抑制剂反应的生物标志物。

Transl Cancer Res. 2025 May 30;14(5):2553-2557. doi: 10.21037/tcr-2024-2516. Epub 2025 May 12.

Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer.全面分析 IDO1 基因在泛癌中的预后价值和免疫作用。

Eur J Med Res. 2024 Mar 27;29(1):206. doi: 10.1186/s40001-024-01766-y.

Prognostic value and immunological role of PD-L1 gene in pan-cancer.PD-L1 基因在泛癌中的预后价值和免疫作用。

BMC Cancer. 2024 Jan 2;24(1):20. doi: 10.1186/s12885-023-11267-6.

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity.全身性炎症影响免疫检查点阻断治疗的临床疗效：优化抗肿瘤免疫治疗。

J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006462.

Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade.血清白蛋白：优化免疫检查点阻断治疗效果的药代动力学标志物。

J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005670.

本文引用的文献

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.肿瘤突变负担预测免疫检查点阻断反应：越多越好。

J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003087.

The Gradient of Immune/Inflammatory Response and COVID-19 Prognosis with Therapeutic Implications.免疫/炎症反应梯度与COVID-19预后及其治疗意义

Front Immunol. 2021 Oct 29;12:739482. doi: 10.3389/fimmu.2021.739482. eCollection 2021.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。

Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。

Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.

The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.美国食品药品监督管理局（FDA）批准帕博利珠单抗用于肿瘤突变负荷（TMB）>10个突变/Mb的患者：这是一个明智的决定吗？不是。

Ann Oncol. 2020 Sep;31(9):1112-1114. doi: 10.1016/j.annonc.2020.07.001. Epub 2020 Aug 5.

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.肿瘤突变负担、毒性和 PD(L)1、CTLA-4 及联合免疫检查点抑制剂的反应：一项荟萃回归分析。

Clin Cancer Res. 2020 Sep 15;26(18):4842-4851. doi: 10.1158/1078-0432.CCR-20-0458. Epub 2020 Jun 25.

A review of cancer immunotherapy: from the past, to the present, to the future.癌症免疫疗法综述：从过去到现在，到未来。

Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1.

Comprehensive T cell repertoire characterization of non-small cell lung cancer.非小细胞肺癌的全面 T 细胞受体谱特征。

Nat Commun. 2020 Jan 30;11(1):603. doi: 10.1038/s41467-019-14273-0.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.肿瘤突变负担作为免疫治疗生物标志物的发展：在肿瘤学临床中的应用。

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验